Abstract library

13 results for "Benecke".
#568 Efficacy of Everolimus and Tolerability with Long-Term Use
Introduction: Predictors of response to Everolimus in neuroendocrine tumors and long-term safety data are lacking.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Maximilian Heetfeld
#957 Outcome Predictors of Gastrinomas: The Role of ENETS Staging, Grading and Interdisciplinary Treatment
Introduction: Gastrinomas are rare neuroendocrine neoplasias (NEN) presenting with Zollinger‐Ellison‐syndrome (ZES).
Conference: 11th Annual ENETS Conference (2014)
Category: Pathology, grading, staging
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Tischer E, Pascher A, ...
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz
#1077 Signs of Carcinoid Heart Disease on Staging CT: Which Predictors are Helpful?
Introduction: In patients with functionally active neueroendocrine neoplasms (NEN) carcinoid heart disease presenting primarily with tricuspid valve regurgitation (TR) is associated with high morbidity and mortality. Early diagnosis is crucial to improve prognosis.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. med. Alexander Baur
Authors: Baur A, Kunz F, Pschowski R, Röpke T, ...
#1136 Small Bowel Neuroendocrine Tumors (NET): Relationship Between Radiologic Features, Functionality and Ki-67 Classification.
Introduction: Since small bowel NETs are usually small tumors, detection and characterization of metastatic affection plays an important role.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Victor Rodriguez-Laval
#1151 Gastric Neuroendocrine Neoplasias-Outcome Predictors-ENETS Staging and Grading System and Treatment
Introduction: Detailed analysis to guide management decisions in gNEN is rare.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: M.A. Stephan Felder
Authors: Felder S, Jann H, Gerlach U, Pascher A, ...
#1474 Curative Resection in Digestive Neuroendocrine Neoplasms: Recurrence-free Survival Rate and Definition of a Risk Score for Recurrence
Introduction: Surgery with radical intent is the only curative option for digestive neuroendocrine neoplasms (DNENs), but clinical practice shows disease-free pts recurring even after years
Conference: 13th Annual ENETS conference (2016)
Category: Surgical treatment
Presenting Author: MD, PhD Elettra Merola
#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study
Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Prof. Dr. Markus Raderer
Authors: Raderer M, Hörsch D, Lahner H, Rinke A, ...
#1577 Peritoneal Carcinomatosis in Digestive Neuroendocrine Neoplasms: Complications and Response to Therapy
Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD, PhD Elettra Merola
#1939 Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors
Introduction: Neuroendocrine tumors of the lung (BP-NETs, typical (AC) and atypical Carcinoids (ATC)) are rare tumors with heterogeneous behavior and molecular characteristics. For the intermediate proliferating BP-NETs treatment options are limited and unsatisfactory. Somatostatin analogues have not only anti-secretory effects, but also display antiproliferative features, as shown by PROMID and CLARINET trial. Nevertheless, their value in BP-NET is undefined so far.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PD Dr. Patricia Grabowski